EOLS:NASDAQEvolus, Inc. Common Stock Analysis

Evolus, Inc. (EOLS) posted a robust 14% revenue growth, driven by Jeuveau market‑share gains and international expansion, and its forward EPS $0.24 signals a potential return to profitability. The company’s forward P/E 17.3 sits well below the industry average of 25.5, and analysts’ median target of $14 implies an upside >250% from the current $4.14 price, suggesting the stock may be substantially undervalued. Recent management participation in the Leerink Global Healthcare Conference underscores confidence in the growth narrative and provides a platform for investor outreach.
On the technical side, the price remains above the identified support of $3.86 but under the 20‑day SMA of $4.84, with a neutral trend, a bearish MACD divergence and a sub‑50 RSI of 38, while trading volume is on a downtrend, indicating limited short‑term momentum. The stock’s beta 1.27 and volatility 103% point to heightened market sensitivity, and the company’s negative operating cash flow and sizable debt amplify liquidity concerns, reinforcing a moderate‑to‑high risk profile.